CEO Sells $882K in Stock After Option Exercise
TARA sits 46% above its 52-week low of $2.77 on elevated volume (1.9× avg).
Summary
Protara Therapeutics' CEO and President, Jesse Shefferman, sold $882,160 worth of common stock after exercising options, marking a notable reduction in direct holdings by a top executive.
Key Events · Ownership and Investor Activity · TARA
-
CEO Sells Shares
Jesse Shefferman, CEO and President, sold 215,687 shares of common stock for $882,159.83 at an average price of $4.09 per share on June 29, 2026.
-
Option Exercise Precedes Sale
The sale followed the exercise of options to acquire 215,687 shares at a price of $1.91 per share, totaling $411,962.17, on the same day.
-
Significant Executive Disposition
This transaction represents a substantial disposition of shares by a key executive, equivalent to 0.39% of the company's market capitalization.
-
Follows Form 144 Filing
This Form 4 filing executes the intent to sell previously reported in a Form 144 filed on June 29, 2026, by an Officer and Director.
Analysis · TARA · Life Sciences
Protara Therapeutics' CEO and President, Jesse Shefferman, sold a substantial amount of stock ($882,160) immediately after exercising options. This transaction represents a significant disposition of shares by a key executive, following a Form 144 filing on the same day indicating intent to sell. Such a sale by a top insider can be interpreted negatively by the market.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 34.9% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TARA was trading at $4.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.1M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.